首页
登录
职称英语
Last year, when President George W. Bush announced that federal funds could
Last year, when President George W. Bush announced that federal funds could
游客
2025-04-08
48
管理
问题
Last year, when President George W. Bush announced that federal funds could be used to support research on human embryonic stem cells, he mandated that only those cell lines that existed at the time would qualify for such support. More than a year later, it’s becoming increasingly clear that these existing cell lines are inadequate. Unless more are created, the research slowdown may exact a staggering cost in terms of human suffering.
Since this announcement, the US National Institutes of Health has tried to stimulate research on. the existing cell lines with new funding and efforts to streamline the initially cumbersome process of obtaining approved cells. However, whether there are 60 cell lines, as originally stated, or nine, as now appear to be available to NIH-funded investigators, the number is not adequate. Given the genetic diversity within the population, scientists need access to new cell lines if they are to come up with the most effective cell therapies.
The issue is partly one of safety. In conducting research with human participants, we must minimize risks. The most effective cell line might not be the safest. When developing a new medicine, a large number of molecules must be screened to find a balance between effectiveness and safety. The same is true with cells. In the context of cell therapy, it will be important to minimize unwanted immune reactions and inflammation this requires selection from a large number of cell lines to obtain the best match.
It’s clear from experiments with animals that stem-cell therapies can reduce human suffering as Parkinsonian mice have been cured with embryonic stem cells that were programmed to become dopamine-secreting, replacement nerve ceils. Soon, cells induced to make insulin in tissue cultures will be used in attempts to treat diabetic mice. Similar successes have been achieved in animal models of spinal-cord injury, heart failure and other degenerative disorders. We are at a frontier in medicine where tissues will be restored in ways that were not imaginable just a few years ago. The ethical issues raised by human-embryo research are profound. The human costs of restricting this research must be taken into account as well. The cost in dollars of delaying new stem-cell research is difficult to estimate. It might measure in the hundreds of billions of dollars, especially if one adds the lost productivity of individuals who must leave work to care for victims of degenerative disorders.
A less obvious, but real, cost is the damage to the fabric of America’s extraordinary culture of inquiry and technical development in biomedical science. Our universities and teaching hospitals are unparalleled. We attract the very best students, scientists and physicians from around the world. But these institutions are fragile. Research and education play key roles in attracting the best physicians. A crippled research enterprise might add an unbearable stress with long-lasting effects on the entire system. If revolutionary new therapies are delayed or outlawed, we could be set back for years, if not decades.
To steer clear of controversy, some investigators will redirect their research. Others will emigrate to countries where such research is allowed and encouraged. Some will drop out entirely. The pall cast over the science community could extend far beyond stem-cell research. Many therapies have emerged from collaboration between government-sponsored researchers and private enterprise. Few of these discoveries would have emerged if, for instance, recombinant DNA research had been outlawed 30 years ago. We face the same type of decision today with limits placed on human embryonic stem cells. Safeguards will be necessary. But if we do not proceed embracing the values of objective, open, inquiry with complete sharing of methods and results, the field will be left to less rigorous fringe groups here and abroad. Patients and society will suffer. [br] The most suitable title for the passage would be______.
选项
A、The Cell Lines
B、The Stem-cell Research
C、The Dangers of Delay
D、Costs on American Patients
答案
C
解析
主旨题。原文首段尾句提到,如果找不到更多的细胞株,研究就会停下来,这将使人类遭受极大的痛苦;第四段首句表明“It’s clear from experiments with animals that stem—cell therapies canreduce human suffering(动物实验证明干细胞疗法能减轻人类的病痛)”。第四、五段提到了干细胞研究停滞会带来的后果,因此这项研究不能拖延。文章结尾指出干细胞研究既要谨慎也要有冒险精神。故答案为C。选项A是细节内容,选项B范围过大,选项D为干扰项。
转载请注明原文地址:https://www.tihaiku.com/zcyy/4031389.html
相关试题推荐
PsychologistGeorgeSpilichandcolleaguesatWashingtonCollegeinChestert
PsychologistGeorgeSpilichandcolleaguesatWashingtonCollegeinChestert
PsychologistGeorgeSpilichandcolleaguesatWashingtonCollegeinChestert
Tobroadentheirvotingappealinthepresidentialelectionof1796,theFed
Tobroadentheirvotingappealinthepresidentialelectionof1796,theFed
Tobroadentheirvotingappealinthepresidentialelectionof1796,theFed
Sixyearslater,inanabout-face,theFBIadmitsthatfederalagentsfired
Sixyearslater,inanabout-face,theFBIadmitsthatfederalagentsfired
Thatwasaman-madedisasterthatclearly(A)couldhaveavertedifthefederalgo
Thatwasaman-madedisasterthatclearly______ifthefederalgovernment,theFe
随机试题
Thearmy’sbravefighting______intotalvictory.A、eliminatedB、illuminatedC、c
A、Thecompetitionamongclassmates.B、Thenecessityofschooleducation.C、Thei
A.间断点 B.连续点 C.可导点 D.连续性不确定的点
(2021年真题)根据《国际评估准则105——评估基本方法和具体方法》,评估师在
产后乳少或全无,乳汁浓稠,乳房胀硬,情志抑郁,纳差,舌黯红,苔微黄脉弦,方选A.
以下属于遗产规划内容的有()。 Ⅰ.确定遗产继承人和继承份额 Ⅱ.为遗产所有
如图7所示各种情况下,力F的作用点为C,力F与水平线的夹角都相等,各杆重量不计。
关于成交量、持仓量、价格三者之间的关系,以下说法正确的是()。A:成交量、持仓
A.艾司唑仑 B.右佐匹克隆 C.阿戈美拉汀 D.多塞平 E.雷美尔通具
下列建设工程项目进度控制措施中,属于经济措施的是()。A.增加进度控制的岗
最新回复
(
0
)